Clinical trials overview

NVG-291 is a first-in-class drug candidate that is being evaluated in a Phase 1b/2a clinical trial. NervGen has initiated a Phase 1b/2a placebo-controlled proof-of-concept trial (NCT05965700) to evaluate the efficacy of NVG-291 in two separate cohorts of individuals with cervical spinal cord injury: chronic (1-10 years post-injury) and subacute (those with a more recent injury), given demonstrated efficacy in preclinical models of both chronic and acute spinal cord injury.

Participating in Clinical Trials

How do I find the right clinical trial?

It is generally best to start your search for a clinical trial by speaking with your treating physician. Talk to them about any trials that might be right for your condition. As they may not be aware of all available trials, you can also search for trials online at,,, or, which are searchable databases of clinical trials done in various parts of the world. Any clinical trials conducted by NervGen will be listed on one or more of these websites.

NVG-291 – clinical trials

NVG-291 is being evaluated in a Phase 1b/2a clinical trial. The company’s lead target indication is spinal cord injury. 

Can I participate in your clinical trial?

Not every clinical trial will be suitable. All clinical trials have guidelines, called eligibility criteria, that outline who can and cannot participate. These include things like age and specific characteristics of an individual’s underlying condition. You can talk about these criteria with your doctor or the study organizers to better understand how you may or may not qualify for a study.

If you find a clinical trial that seems of interest, contact the study organizers (phone and/or email address is listed on the website). They can put you in touch with the team of medical professionals running the trial. This team will then discuss next steps to see if you might be a good fit for the trial.

Expanded Access program

NervGen does not currently offer an Expanded Access program. Click here for information on NVG-291 and Expanded Access.